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Tamoxifen, a potent anticancer agent known to interrupt the enhanced estrogen activity of malignant mammary gland cells, was
recently approved by the Food and Drug Administration (FDA) for the treatment of breast cancer. In this investigation, the toxic
effects of tamoxifen were evaluated through cell multiplication, and cytological, surface ultrastructural, and biochemical studies
on human cervical carcinoma cells (HeLa) and/or murine erythroleukemic (MEL) cells (BB-88). Tamoxifen treatment demon-
strated an inhibitory effect on HeLa cell multiplication at lower concentrations and toxicity at higher concentrations and longer
treatment durations. The drug also triggered morphological and biochemical changes as revealed by light microscopy, scanning
electron microscopy (SEM), ﬂuorescence microscopy, Nucleosome ELISA, and the DNA smear pattern. Cytological observations
showed nuclear condensation, cell shrinkage, multinucleation, and apoptotic bodies. Surface ultrastructure of tamoxifen treated
cells examined under the SEM revealed abnormalities such as membrane blebbing, holes, and cytoplasmic extrusions, all of which
are characteristics of programmed cell death (apoptosis). Redistribution of the membrane phospholipid phosphatidylserine (PS)
from the protoplasmic surface of the plasma membrane to the cell surface was identiﬁed using annexinV-enhanced green ﬂuo-
rescent protein (EGFP) in tamoxifen treated MEL BB-88 cells, a general feature of cells undergoing apoptosis. Tamoxifen treated
cells demonstrated internucleosomal damages of the genomic DNA and DNA fragmentations, evidenced by an increase in free
nucleosomes, and distinctive DNA smear patterns on the agarose gel.
INTRODUCTION
Tamoxifen,or Nolvadex ,is a synthetic antiestrogen that
has been used since the 1970s to treat advanced and early
stage breast cancer [1]. The drug is classiﬁed as a selective
estrogen receptor modulator (SERM) because it behaves like
an estrogen agonist in some tissues and an antagonist in oth-
ers [2]. The mechanism of tamoxifen’s antitumor activity is
primarily due to its antiestrogen action [3]. Estrogen, when
acting as a harmful hormone,has the ability to promote can-
cer of the breast and uterine lining. Tamoxifen is a synthetic
estrogen-like hormone that binds to the estrogen receptors
and acts as a competitor of natural estrogen to inhibit the
growth of malignant mammary tumors [2].
There are two types of cell death mechanisms: necrosis
and apoptosis (programmed cell death). Necrosis is initiated
byintensetoxicstress,anditsactionisnonspeciﬁctocellsand
tissues. Apoptosis is a normal mechanism of development
and tissue homeostasis [4]. This “cell suicide” phenomenon
isinitiatedbyoneormoreexternalsignals,suchasthelackof
a necessary hormone or by cellular exposure to chemother-
apeutic chemicals, which activates a cascade of events that
includes the activation of endonucleases [5]. Programmed
cell death, or apoptosis, is deﬁned by various morphological
and biochemical changes. In the early stages, characteristics
of apoptosis include cell shrinkage, nuclear condensation,
DNA degradation, and breakdown of the nuclear material.
Later stages of apoptosis are characterized by the formation
of membrane blebs leading to “apoptotic bodies” and cell
fragmentation that are phagocytized by macrophages [6–9].
Most of these morphological changes can be detected with
thelightandscanningelectronmicroscopes,whilemolecular
modiﬁcation of the cell membrane changes can be visualized
by observing the redistribution of phosphatidylserine (PS)
from the inner leaﬂet of the plasma membrane to the cell
surface using the immunoﬂuorescence annexinV-enhanced
greenﬂuorescentprotein(EGFP)thathasastrongafﬁnityfor
PS [10, 11].
Limitedinvitrostudiesontheeffectsoftamoxifeninnon-
breast cancer cell proliferation reported conﬂicting results.A
study by Grenman et al. [12] found an inhibitory effect of
the drug on several human cancer cell lines. Khar et al. [13],
on the other hand, found no inhibitory action of tamoxifen
in the presence of fetal calf serum on HeLa cells. In another
study,Bonitaetal.[14]reportedtheantiproliferativeeffectof
the agent on both the HeLa and the murine erythroleukemic
cells (MEL BB-88), however, the inhibitory inﬂuence of the
drug was diminished in the presence of B-estradiol. Other
studies suggested that tamoxifen induced programmed cell
deathinMCF-7humanbreastcancercells[15,16].Thestudy
performed by Grenman et al. [12] found the inhibitory ef-
fect of tamoxifen (1–10mM) on HeLa cell proliferation after
6 days. However, the drug’s effects at higher concentrations100 S. K. Majumdar et al. 1:3 (2001)
over shorter time periods (less than 72hours) were not eval-
uated.Osborneetal.[17],ontheotherhand,foundagrowth
inhibitory effect of the drug on human breast cancer cells
(MCF-7).
In this investigation, the morphological and biochemi-
cal effects of tamoxifen on human cervical carcinoma cells
(HeLa)andmurineerythroleukemiccells(MELBB-88)were
examined. In vitro studies were conducted to determine
the drug’s role on HeLa cell multiplication and its involve-
ment in cell death. To investigate the cell death mechanism,
morphological characteristics of cells and cell membrane
were studied using light and scanning electron microscopy.
Assays including annexinV-EGFP, an immunoﬂuorescense
technique,NucleosomeELISA,andDNAladderingtechnique
were employed.
MATERIALS AND METHODS
Maintenanceofcelllines
HeLa (human cervical carcinoma cells) and BB-
88 (murine erythroleukemia cells MEL) cell lines were
purchased from the American Type Culture Collection
(Rockville, MD). BB-88 cells (MEL BB-88) grow in suspen-
sion,whereasHeLaareepithelialcellsthatgrowasmultilayers
on the tissue culture ﬂasks surface. Both cell lines were pur-
chased from Sigma-Aldrich (St. Louis, MO) and maintained
in Dulbecco’s Modiﬁed Eagle’s Medium, supplemented with
10% fetal calf serum (DME-10) and grown in 25cm2 tis-
sue culture ﬂasks at 37◦ Ci n7.5% CO2 in air (as outlined by
Ahearnetal.[18]andRuddyetal.[19]).Cellswererecultured
twice per week.
Drugtreatment
Tamoxifen was purchased from Sigma-Aldrich in St.
Louis, MO and dissolved in 0.2ml dimethyl sulfoxide
(DMSO) to a ﬁnal concentration of 400µg/ml in sterile
deionized water. The solution for control treatments was
madebydissolving0.2mlDMSOinthesameamountof ster-
ile deionized water. Both stock solutions were kept at 8 ◦C.
Cellmultiplicationstudy
In contrast to our previous study [14], logarithmically
growingHeLacellswereseededat 1.3×104 cells/mlinDME-
10 in six well culture plates. After 24hours, the cells were
treated with 0,3,5,10,15, and 20µg/ml tamoxifen. To be
sure that nutrient depletion would not be a factor in cell
growth inhibition, the medium and drug were removed and
replaced with fresh DME-10 and tamoxifen on each day of
the study. Cell number was determined after 24, 48, 72, and
96hours using the Trypan Blue exclusion method. Control
and tamoxifen treated cells were photographed directly in
thecultureplateusinganinvertedlightmicroscopeequipped
with a Nikon camera.
Lightmicroscopy
Exponentially growing HeLa cells were treated with 5,10,
15,and20µg/mltamoxifenorthecontrolsolutionfor24,48,
72,and96hours.Cellswereharvestedandﬁxedwith0.075M
KClhypotonicsolutionfor10minutesat8◦C.Cellswerethen
ﬁxed four times in a 3:1methanol : glacial acetic acid, and
slides were prepared and stained with KaryoMAX Giemsa
Stain (Gibco BRL, Grand Island, NY). Cells were examined
and scored for enucleation, cell shrinkage, nuclear blebs, py-
knotic fragments, nuclear condensation, and apoptotic bod-
ies,characteristic features of apoptotic cells [6–9,20].
Scanningelectronmicroscopy(SEM)
Approximately 25.000cells/mlof resuspendedHeLacells
were plated on glass coverslips in a petri dish and incubated
for24hours.Petriplateswereﬂoodedwith4mlDME-10con-
taining 5, 10, 15, or 20µg/ml of tamoxifen for 24, 48, 72, or
96hours. Control petri dishes received 4ml of DME-10 con-
taining a comparable concentration of DMSO in deionized
water. Exponentially growing MEL BB-88 cells were treated
with0,5,10,or15µg/mloftamoxifenin25cm2 tissueculture
ﬂasks and sampled after 24 and 48hours of exposure.
Samples were ﬁxed in 2% glutaraldehyde for 1hour fol-
lowed by 1% osmium tetroxide for 1hour. Cells were dehy-
drated in an increasing acetone series, critically point dried
(PolaronE 3000), coated with gold-palladium, and observed
under an ISI Super III-A scanning electron microscope. Pho-
tographsobtainedwithaMamiyacamera(PolaroidB-52and
55 ﬁlms) were used to study the surface ultrastructural mor-
phology.
Immunoﬂuorescencestaining
(BioVision ,PaloAlto,CA)
ExponentiallygrowingMELBB-88cellsweretreatedwith
5,10,and15µg/mlof tamoxifenorthecontrolsolutionfor4,
8, 12, and 24hours. Cells were collected by centrifugation,
resuspended in 1x binding buffer, and slide spreads were
made. Samples were then ﬁxed with annexinV-enhanced
green ﬂuorescent protein (EGFP) and propidium iodide (PI)
for 5minutes, and the slides were prepared following the
method outlined by BioVision [21]. Treated and untreated
cells were viewed under a ﬂuorescence microscope with a
dual ﬁlter set of FITC and rhodamine in order to detect cell
membrane disruption in treated and untreated cells.
NucleosomeELISAassay
(OncogeneTM researchproducts,Cambridge,MA)
HeLa cells were seeded at 100.000cells/ml in 25cm2 tis-
sue culture ﬂasks for 24hours and then treated with 0 and
10µg/ml tamoxifen for 4, 6, and 10hours. Free nucleosomes
were then detected using the Nucleosome ELISA assay steps
outlined by Oncogene [22]. The absorbance of resulting yel-
lowproductswasmeasuredat450nminaBio-TekMicroplate
Reader (EL312).
TACSTM ethidiumbromideapoptoticDNAladderingkit
(Trevigen,Inc.,Gaithersburg,MD)
Exponentially growing BB-88 cells were exposed to 5,10,
and 15µg/ml of tamoxifen for 12, 24, and 48hours. Follow-
ing the provided Trevigen protocol, cells were harvested by1:3 (2001) Toxicity evaluations of tamoxifen on two non-breast cancer cell types 101
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Figure 1: Growth inhibitory effect of tamoxifen on HeLa cells. Per-
cent of control number of viable cells/ml as a function of time after
tamoxifen treatment in 6-well culture plates.
centrifugation and the pellet was resuspended in a sample
buffer [23]. The DNA was stabilized by lysing the sample
to obtain a puriﬁed aqueous layer. Sodium acetate and 2-
propanol were added to the aqueous sample. The sample was
then centrifuged, the pellet was washed with 70% ethanol,
vacuumdried,resuspendedinDNase-freewater,andthecon-
centrationoftheDNAwasquantiﬁedspectrophotometrically
(Milton Roy Spectromic 1201).
One µg of DNA sample was placed in each well and sep-
arated according to size by electrophoresis on a 0.8% agarose
gel at 70V for 1.5hours. The DNA smear was stained with
ethidium bromide,visualized under the UV transilluminator,
and photographed.
RESULTS
Cellmultiplicationstudy
HeLa cell growth inhibition was both time and drug-
concentration dependent in an inverse relationship in ex-
cess of 5µg/ml (see Figure 1).A minimum growth inhibitory
effect was seen at 3 and 5µg/ml tamoxifen treatments. At
5µg/ml, the number ofcells/ml initially decreased (about
65% of the control) and then followed a trend similar to
the 3µg/ml treated group, but at a slower growth rate after
24hours. The number of viable HeLa cells treated with
10µg/ml, compared to the control, began to decrease (45%)
after only 24hours and continued to decrease to 20% of the
control by 96hours. A drastic reduction in viable cell num-
ber was seen by 24hours of tamoxifen treatment at 15 and
20µg/mlandresultedincompletedeathby96hours(seeFig-
ure 1).
Lightmicroscopy
Untreated HeLa cells exhibited typical growth patterns
and normal morphology (see Figure 2a). The leading edge
of the cell is spread into a ﬂattened “veil-like” projection
Figure 2: Morphological characteristics of untreated and tamox-
ifen treated HeLa cells under the light microscope. (a) Conﬂuent
control cells at 72hours showing normal morphology with lamel-
lipodium, prominent nucleus, and nucleoli in each cell × 400. (b)
Tamoxifentreatedcells(10µg/ml)at48hoursshowingnuclearcon-
densation, cell shrinkage, and enucleation (arrow) × 400. (c) Cells
treated with tamoxifen (15µg/ml) at 48hours showing multinucle-
ation and apoptotic bodies (arrows) × 900.102 S. K. Majumdar et al. 1:3 (2001)
called a lamellipodium, whereas the trailing end of the cell
is narrowed into a tail. Each control cell had one distinct
nucleus with several nucleoli. Light microscopic observa-
tions of treated HeLa cells showed shrinkage, nuclear con-
densation, and occasional enucleation (see Figure 2b). Mult-
inucleation and apoptotic bodies, which are characteristic
of programmed cell death (apoptosis), were also detected
in treatment groups (see Figure 2c). Tamoxifen treatment
at 10µg/ml or higher exhibited elongated lamellipodia and
many detached cells. Frequency of dead cells increased in
abundancein15and20µg/mltamoxifentreatedgroupseven
after 24hours of exposure.
Scanningelectronmicroscopy(SEM)
Surface ultrastructure of tamoxifen treated cells, exam-
inedwiththescanningelectronmicroscope,revealeddistinct
morphological changes when exposed to tamoxifen. Expo-
nentially growing (24 and 48hours) untreated BB-88 cells
are spherical in shape with a few blebs scattered over the in-
tact cell membrane (see Figure 3a). Treated BB-88 cells at 24
and 48hours were distorted in shape and exhibited clump-
ing. Abnormalities such as cell shrinkage, severe membrane
blebbing (see Figure 3b), holes, and cytoplasmic extrusions
(see Figure 3c) were detected in the treatment groups.
Control HeLa cells are ﬂattened in shape and show nu-
merous microvilli on the cell surface with extending lamel-
lipodia and membrane connections (see Figure 4a). Occa-
sional presence of rounded cells and blebbings on the cell
surface are characteristics of HeLa cells in culture. In con-
trast, treated HeLa cells exhibited shrinkage and narrowing
of lamellipodia with blunt microvilli. Compared to control
cells, the tamoxifen treated cells produced many detached
osmiophilic electron dense cells with conspicuous blebs, or
apoptotic like bodies on the cell surface (see Figures 4b and
4c).
DetectionoftheboundannexinV-EGFP
Untreated BB-88 cells were spherical in shape and both
the nucleus and the plasma membrane appeared red due to
the nuclear counterstain propidium iodide (PI) (see Figures
5a and 5b). On occasions, dying or dead cells were detected
in the untreated group with blebs and bound annexinV-
enhanced ﬂuorescent green protein (EGFP) which stained
the cell membrane green. A higher proportion of tamox-
ifen treated BB-88 cells showed green staining in the plasma
membrane resulted from the bound annexin-V protein to
the redistributed phosatidylserine (PS) translocated on the
surface of cells possibly undergoing apoptosis (see Figures 5c
and 5d). Apoptosis is indicated by a green staining (EGFP)
plasma membrane surrounding the lightly stained (PI) nu-
cleus, as seen in Figures 5c and 5d [21].
NucleosomeELISAassay
Tamoxifen treatment (10µg/ml) of HeLa cells for 4, 6,
and 10hours yielded a higher absorbance than their re-
spective controls (see Figure 6). A trend was identiﬁed that
showed an increase in absorbance among the tamoxifen
Figure 3: Surface ultrastructural characteristics of BB-88 cells
treated with or without tamoxifen as depicted under the SEM. (a)
Control BB-88 cells at 48hours (× 2400). (b) Tamoxifen treated
BB-88 cells (24hours, 10µg/ml) showing clumping, cell shrinkage,
and membrane blebbing (B) (× 3000). (c) BB-88 cells treated with
tamoxifen (48hours, 10µg/ml) showing clumping, cell membrane
blebbing (B), holes (H), and cytoplasmic extrusions (E) (× 3500).1:3 (2001) Toxicity evaluations of tamoxifen on two non-breast cancer cell types 103
Figure4:SEMmicrographsofsurfaceultrastructuralcharacteristics
of HeLa cells treated with and without tamoxifen. (a) Cell surface
characteristics of 48hours untreated HeLa cells showing numer-
ous microvilli on the cell surface and lamellipodia extensions (L)
(×1500). (b) Tamoxifen treated HeLa cells (48hours, 5µg/ml) ex-
hibiting cell surface blebbing (B) and narrowing of cells with elon-
gated and shortened lamellipodia (L). Cell detachment is visible
(×1800).(c) 48hourstreated(15µg/ml)HeLacellsdepictingmany
blebs or apoptotic bodies (B) on the cell surface, broken lamellipo-
dia,and cytoplasmic extrusions (E). Cell shrinkage and detachment
a r ee v i d e n t( ×1500).
treated lysates samples indicating an increase in the degra-
dation of genomic chromatin into free nucleosomes. The
increasesinabsorbanceforthe4and6hourstamoxifentreat-
ments, compared to their corresponding controls, were not
signiﬁcantly different. However, the increase in absorbance
for the 10hours treatment group was statistically signiﬁcant
(ANOVA, P < 0.05).
DNAladderingpattern
DNA was isolated from tamoxifen treated BB-88 cells
and subjected to agarose gel electrophoresis to visualize the
DNA laddering pattern. Tamoxifen induced degradation of
genomic DNA was indicated by DNA smear patterns that
aredifferentfromthoseof thecontrols.Tamoxifentreatment
lanesrevealedbandingintheﬁrsthalf of thegelsimilartothe
control, but visible DNA smearing patterns continued, con-
tiguous to the smaller KB ladder fragments (see Figure 7). A
faint DNA smearing observed in lane 4 (12hours/ 15µg/ml)
was possibly due to the drastic effect of the drug on the cell
viabilitywhichmighthaveresultedinaseveredegradationof
nucleosomes.
DISCUSSION
Tamoxifen, a promising anticancer drug, is reported to
exertantiproliferativeandcytotoxiceffectsinbreastandnon-
breast cancer cells [16]. A study performed by Khar and Ali
[13]showedthattamoxifenhadnoeffectonHeLacellswhen
they were grown in the presence of fetal calf serum and that
tamoxifen’s toxic effects were only seen under serum-free
conditions. Our study, however, showed an impediment of
HeLa cell multiplication with as little as 5µg/ml tamoxifen
grown in DME supplemented with 10% fetal calf serum. At
higher concentrations, the agent exerted drastic effects on
cell growth and viability. In addition, our cell multiplication
study ensured that the cell growth inhibition was due to the
drug and not a limited amount of nutrients or waste build-
up because the drug and media were removed and replaced
daily. Similar adverse effects of the agent were reported on
murineerythroleukemicBB-88cells[14,24].Atlowertamox-
ifen concentrations (3 and 5µg/ml), HeLa cell growth was
minimally inhibited.At 5µg/ml,however,the initial decrease
in cell number and subsequent increase in cell growth could
be due to a shock effect leading to a longer lag phase. After
the lag phase, however, the cells in 5µg/ml multiplied at a
slower rate.
Disruption of normally integrated cell cycle progres-
sion can trigger a cascade of morphological and biological
events. Morphological studies performed in this investiga-
tionthroughlightmicroscopyandscanningelectronmicros-
copy lend evidence that an apoptotic pathway is occurring
with tamoxifen treatment. Although a few cells from the
control groups resembled those from treated groups,tamox-
ifen caused morphological alterations in a large proportion
of cells. Other studies support these ﬁndings; for example,
whencellinjurywasinduced,cellsundergoingapoptosiswere
characterized by shrinkage of cells, condensation of nuclear
material, cell membrane blebbing, apoptotic bodies, and104 S. K. Majumdar et al. 1:3 (2001)
Figure 5: Immunoﬂuorascence staining with annexin V-enhanced green ﬂuorescent protein (EGFP) and propidium iodide (PI). (a), (b)
Control BB-88 cells (24hours) showing red staining due to PI throughout the cell (× 400). (c), (d) Tamoxifen treated BB-88 cells (8hours,
5µg/ml) showing annexinV-EGFP green staining in the plasma membrane ((c) × 400, (d) × 900) and blebs on cells undergoing apoptosis.
narrowing of lamellipodia [5, 16, 25]. Cytological results of
Perry et al. [16] and Welsh [26] showed inhibitory effects of
tamoxifen on breast cancer cells (MCF-7) and demonstrated
evidence of apoptosis in treated cells. They documented
incidences of enucleation,blebbing,pyknotic fragments,and
apoptotic bodies; similar changes were also found in this
study in treated HeLa and/or BB-88 cell lines.
Adherentepithelialcellscharacteristicallyproducelamel-
lipodia with leading and trailing edges [27]. The lamel-
lipodium involves an assembly of actin monomers into ﬁl-
aments and contains many actin,cross-linking,severing,and
bundling proteins. Previous studies with human melanoma
cells have shown that cells which failed to express the
crosslinking protein ABP280 were unable to form lamellipo-
dia and formed spherical blebs at the membrane surfaces
[28]. The shape distortions and membrane blebbing are sug-
gested to be stemmed from actin ﬁlament dysfunction [27].
The formation of blebs or apoptotic bodies is probably due
toinactivationof focaladhesionkinase(FAK),whichleadsto
a disruption of cell adhesion and a subsequent detachment
of cells from the substratum and their neighbors [29].
Immunoﬂuorescence studies further conﬁrmed the
evidence of apoptosis in tamoxifen treated murine ery-
throleukemic cells (BB-88). The plasma membrane is com-
posed of a distribution of phospholipids, such as phos-
phatidyleserine (PS). AnnexinV-EGFP is a protein that has
a strong afﬁnity for the exposed PS on the cell surface and
stains the plasma membrane green when examined by ﬂuo-
rescence microscopy [14]. In this study plasma membranes
of many tamoxifen treated cells appeared green possibly due
to the binding of annexinV-EGFP to the exposed PS on the
cell surface. The redistribution of the plasma membrane PS
is one of several events in cells undergoing apoptosis [10].
Studies have suggested that PS may serve as a“ﬂag”or identi-
fying surface marker that help the removal of apoptotic cells
by macrophages [10, 11].
Our ﬁnding is in agreement with the study made by Mar-
tin et al. [10] and Verhoven et al. [11], who observed ﬂu-
orescent bound PS translocation in apoptotic Jurkat cells
and T lymphocytes, respectively. Cell membranes of many
treated BB-88 cells were covered with spherical blebs. An-
nexin binding to apoptotic cells is normally concentrated in1:3 (2001) Toxicity evaluations of tamoxifen on two non-breast cancer cell types 105
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Figure 6:Degradation of chromatin into free nucleosomes of HeLa
cells treated with 10µg/ml tamoxifen (black bars) compared to the
control(graybars),detectedbytheNucleosomeELISAassay.Absor-
bance (450nm) is a function of time after the drug treatment. Ten
hour treatment period is signiﬁcantly different from the control.
themembranesofcellsurfaceblebs.Ithasbeensuggestedthat
translocationofPSfromtheinnerleaﬂettotheouterleaﬂetof
the cell membrane can be attributed to enzymes such as ﬂip-
pase,scrambalase,ortranslocasewhichfacilitatebidirectional
bilayermovementof allphospholipidsduetoitsstrongafﬁn-
ity for them [11].
In previous investigations, DNA damage was observed
in various cell types undergoing apoptosis [5, 30–32]. Many
chemicalsandanticancerdrugsareknowntoinduceapopto-
sis [15,16,32,33]. During apoptosis,endonucleases are acti-
vated that cleave the genome at DNA linker regions between
adjacent nucleosomes, causing the formation of mono- and
oligonucleosomes [5,31]. The Nucleosome ELISA is a quan-
tatative assay that detects DNA fragments through a colori-
metric reaction due to histone protein binding. In this study,
a signiﬁcant increase in DNA fragmentation was detected by
Nucleosome ELISA at 10hours of tamoxifen treatment, in-
dicating an induction of apoptosis by tamoxifen. However,
at 4 and 6hours duration, the beginning stages of apoptosis
might have resulted in limited chromatin degradation.
The DNA laddering is a hallmark of apoptosis [16, 34].
ApoptoticcleavageofgenomicDNAcanbeidentiﬁedasDNA
fragments or smear on agarose gels. The smearing patterns
observed in this study occurred in the treated cell lanes
towards the smaller KB fragments, as opposed to the con-
trol cell lane. The smearing is caused by the cleavage of DNA
into low molecular weight fragments that travel according to
size on an agarose gel. This is in agreement with a study per-
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Figure 7: Agarose gel (0.8%) of DNA extracted from BB-88 cells:
Lane 1, KB Ladder; Lane 2, Control (12hours); Lane 3, tamox-
ifen treatment (12hours, 10µg/ml); Lane 4, tamoxifen treatment
(12hours, 15µg/ml). Only a faint DNA smearing is visible in the
15µg/ml treatment group.
formed by Perry et al. [16], who reported tamoxifen’s DNA
cleavingabilityandsubsequentapoptosisinthebreastcancer
cell line MCF-7. Our study showed DNA degradation ability
oftheagentinthenon-breastcancermurineerythroleukemic
cells (MEL BB-88).
Apoptosis is a complex system initiated by various inter-
nal signaling pathways. There are evidences which show
that mitochondria play a central role in triggering the pro-
grammed cell death [35, 36]. On the other hand, numerous
experimentations have shown that caspase activated DNase
(CAD) degrades genomic DNA in the activation of apopto-
sis [25, 37–40]. It is clear from these and other studies that
apoptosisisundergeneticcontrol,suchasbytumorsuppres-
sorgenes(i.e.,p53,BRAC1,andBRAC2)andoncogenes(i.e.,
myc and the Bcl-2 family), see [25, 34, 36, 41].
It is necessary that the basic mechanism of tamoxifen’s
action on various cell types be known in order to maximize
its effects on cancer cells. The sequence of events leading to
apoptosis induced by tamoxifen is still unclear. Many clinical
studies have examined the chemotherapeutic nature of this
chemical in breast cancer patients [42, 43]. In vitro studies
with tamoxifen and its metabolite,4-hydroxytamoxifen have
been done utilizing estrogen receptor positive cell lines and,106 S. K. Majumdar et al. 1:3 (2001)
as in this study, estrogen receptor negative cell lines [16, 44].
Cytotoxic effects were documented in these investigations.
Therefore, tamoxifen’s anticancer action may not be solely
dependent on the interference of estrogen receptor sites.
Despite these uncertainties, the cytostatic and cytotoxic
effects of tamoxifen on various cancer cells are clear and sup-
port tamoxifen’s role as a chemotherapeutic agent on certain
cancer types. In this investigation, tamoxifen, depending on
the concentrations and exposure duration, was found to be
cytostatic or cytotoxic, and caused morphological changes
andDNAdegradationinthetwonon-breastcancercelllines.
Theresultssuggestthattamoxifeninducedcelldeaththrough
an apoptotic pathway.
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